Farmacologia delle statine: evidenze di un'azione antiaterosclerotica diretta.

Translated title of the contribution: The pharmacology of the statins: the evidence of a direct antiatherosclerotic action

M. Raiteri, L. Arnaboldi, P. Quarato, R. Paoletti, R. Fumagalli, A. Corsini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

With the increasing knowledge on the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. Among them, a pivotal role is played by smooth muscle cell migration and proliferation that, together with lipid deposition, are prominent features of atherogenesis and restenosis after angioplasty. Mevalonate and other intermediates (isoprenoids) of cholesterol synthesis are essential for cell growth, hence drugs affecting this metabolic pathway are potential antiatherosclerotic agents. Recently we provided evidence that fluvastatin, simvastatin, lovastatin, but not pravastatin, dose-dependently decrease smooth muscle cell migration and proliferation, independently of their hypocholesterolemic properties. The in vitro inhibition of cell migration and proliferation induced by simvastatin and fluvastatin (70-90% decrease) was completely prevented by the addition of mevalonate and partially (80%) by farnesol and geranylgeraniol, confirming the specific role of isoprenoid metabolites--probably through prenylated proteins--in regulating these cellular events. The present results provide evidence that HMG-CoA reductase inhibitors interfere directly with processes involved in atherogenesis--beyond their effects on plasma lipids--partially through local inhibition of isoprenoid biosynthesis.

Original languageItalian
JournalAnnali Italiani di Medicina Interna
Volume10 Suppl
Publication statusPublished - Oct 1995

Fingerprint

fluvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Terpenes
Mevalonic Acid
Atherosclerosis
Simvastatin
Cell Proliferation
Pharmacology
Smooth Muscle Myocytes
Cell Movement
Farnesol
Lipids
Pravastatin
Lovastatin
Metabolic Networks and Pathways
Angioplasty
Cardiovascular Diseases
Cholesterol
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Raiteri, M., Arnaboldi, L., Quarato, P., Paoletti, R., Fumagalli, R., & Corsini, A. (1995). Farmacologia delle statine: evidenze di un'azione antiaterosclerotica diretta. Annali Italiani di Medicina Interna, 10 Suppl.

Farmacologia delle statine : evidenze di un'azione antiaterosclerotica diretta. / Raiteri, M.; Arnaboldi, L.; Quarato, P.; Paoletti, R.; Fumagalli, R.; Corsini, A.

In: Annali Italiani di Medicina Interna, Vol. 10 Suppl, 10.1995.

Research output: Contribution to journalArticle

Raiteri, M, Arnaboldi, L, Quarato, P, Paoletti, R, Fumagalli, R & Corsini, A 1995, 'Farmacologia delle statine: evidenze di un'azione antiaterosclerotica diretta.', Annali Italiani di Medicina Interna, vol. 10 Suppl.
Raiteri M, Arnaboldi L, Quarato P, Paoletti R, Fumagalli R, Corsini A. Farmacologia delle statine: evidenze di un'azione antiaterosclerotica diretta. Annali Italiani di Medicina Interna. 1995 Oct;10 Suppl.
Raiteri, M. ; Arnaboldi, L. ; Quarato, P. ; Paoletti, R. ; Fumagalli, R. ; Corsini, A. / Farmacologia delle statine : evidenze di un'azione antiaterosclerotica diretta. In: Annali Italiani di Medicina Interna. 1995 ; Vol. 10 Suppl.
@article{e9dc9fb6f5c0418698c521f2a02507a3,
title = "Farmacologia delle statine: evidenze di un'azione antiaterosclerotica diretta.",
abstract = "With the increasing knowledge on the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. Among them, a pivotal role is played by smooth muscle cell migration and proliferation that, together with lipid deposition, are prominent features of atherogenesis and restenosis after angioplasty. Mevalonate and other intermediates (isoprenoids) of cholesterol synthesis are essential for cell growth, hence drugs affecting this metabolic pathway are potential antiatherosclerotic agents. Recently we provided evidence that fluvastatin, simvastatin, lovastatin, but not pravastatin, dose-dependently decrease smooth muscle cell migration and proliferation, independently of their hypocholesterolemic properties. The in vitro inhibition of cell migration and proliferation induced by simvastatin and fluvastatin (70-90{\%} decrease) was completely prevented by the addition of mevalonate and partially (80{\%}) by farnesol and geranylgeraniol, confirming the specific role of isoprenoid metabolites--probably through prenylated proteins--in regulating these cellular events. The present results provide evidence that HMG-CoA reductase inhibitors interfere directly with processes involved in atherogenesis--beyond their effects on plasma lipids--partially through local inhibition of isoprenoid biosynthesis.",
author = "M. Raiteri and L. Arnaboldi and P. Quarato and R. Paoletti and R. Fumagalli and A. Corsini",
year = "1995",
month = "10",
language = "Italian",
volume = "10 Suppl",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",

}

TY - JOUR

T1 - Farmacologia delle statine

T2 - evidenze di un'azione antiaterosclerotica diretta.

AU - Raiteri, M.

AU - Arnaboldi, L.

AU - Quarato, P.

AU - Paoletti, R.

AU - Fumagalli, R.

AU - Corsini, A.

PY - 1995/10

Y1 - 1995/10

N2 - With the increasing knowledge on the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. Among them, a pivotal role is played by smooth muscle cell migration and proliferation that, together with lipid deposition, are prominent features of atherogenesis and restenosis after angioplasty. Mevalonate and other intermediates (isoprenoids) of cholesterol synthesis are essential for cell growth, hence drugs affecting this metabolic pathway are potential antiatherosclerotic agents. Recently we provided evidence that fluvastatin, simvastatin, lovastatin, but not pravastatin, dose-dependently decrease smooth muscle cell migration and proliferation, independently of their hypocholesterolemic properties. The in vitro inhibition of cell migration and proliferation induced by simvastatin and fluvastatin (70-90% decrease) was completely prevented by the addition of mevalonate and partially (80%) by farnesol and geranylgeraniol, confirming the specific role of isoprenoid metabolites--probably through prenylated proteins--in regulating these cellular events. The present results provide evidence that HMG-CoA reductase inhibitors interfere directly with processes involved in atherogenesis--beyond their effects on plasma lipids--partially through local inhibition of isoprenoid biosynthesis.

AB - With the increasing knowledge on the pathogenesis of atherosclerosis, it appears that the prevention of cardiovascular disease in the future will involve, besides risk factor correction, direct pharmacological control of processes occurring in the arterial wall. Among them, a pivotal role is played by smooth muscle cell migration and proliferation that, together with lipid deposition, are prominent features of atherogenesis and restenosis after angioplasty. Mevalonate and other intermediates (isoprenoids) of cholesterol synthesis are essential for cell growth, hence drugs affecting this metabolic pathway are potential antiatherosclerotic agents. Recently we provided evidence that fluvastatin, simvastatin, lovastatin, but not pravastatin, dose-dependently decrease smooth muscle cell migration and proliferation, independently of their hypocholesterolemic properties. The in vitro inhibition of cell migration and proliferation induced by simvastatin and fluvastatin (70-90% decrease) was completely prevented by the addition of mevalonate and partially (80%) by farnesol and geranylgeraniol, confirming the specific role of isoprenoid metabolites--probably through prenylated proteins--in regulating these cellular events. The present results provide evidence that HMG-CoA reductase inhibitors interfere directly with processes involved in atherogenesis--beyond their effects on plasma lipids--partially through local inhibition of isoprenoid biosynthesis.

UR - http://www.scopus.com/inward/record.url?scp=0029382480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029382480&partnerID=8YFLogxK

M3 - Articolo

C2 - 8562263

AN - SCOPUS:0029382480

VL - 10 Suppl

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

ER -